A sugar called Neu5Gc, present in red meat, some fish and dairy products, is related to the appearance of spontaneous tumors in humans. Researchers at the University of Nevada, Reno, led by Spaniard David Álvarez Ponce, have analyzed the evolutionary history of the CMAH gene – which allows the synthesis of this sugar – and...
Category: <span>Cancer</span>
Post
Could our body clock help to prevent cancer?
A new study published in the journal PLOS Biology suggests that the way that experts approach optimizing cancer treatment may need to be rethought to include factors relating to the biological, or “circadian,” clock. Researchers suggest that our biological clock may help to prevent or treat cancer. We all have a biological clock, which is tasked...
Post
Landmark CAR-T cancer study published
How CAR-T cell therapy harnesses a patient’s immune system to fight cancer. Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient’s immune system to attack cancer cells. Patrick Stiff, MD, director of Loyola’s Cardinal Bernardin Cancer Center,...
Post
Global CAR T therapy trial shows high rates of durable remission for NHL
In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin’s lymphoma (NHL) patients. Results from a global, multisite trial will be presented today at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta...
Post
Phase 2 CAR-T study reports significant remission rates at 15-month follow up
A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment with axi-cel (marketed as Yescarta). The study, named ZUMA-1, also reported measurable responses in 82 percent of patients and complete responses in...
Post
Researchers identify epigenetic orchestrator of pancreatic cancer cells
Genentech researchers have identified an enzyme that shifts pancreatic cancer cells to a more aggressive, drug-resistant state by epigenetically modifying the cells’ chromatin. The study, which will be published December 11 in the Journal of Cell Biology, suggests that targeting this enzyme could make pancreatic cancer cells more vulnerable to existing therapies that currently have only...
Post
How inhibiting one protein could help to treat pancreatic cancer
Targeting an enzyme that makes pancreatic cancer cells more aggressive by silencing some of their genes could make the deadly disease less resistant to treatment. Could the findings of a new study help in the fight against pancreatic cancer? This was the conclusion of new research from Genentech, a biotechnology company in South San Francisco,...
Post
ASH: A+AVD beats ABVD for advanced Hodgkin’s lymphoma
(HealthDay)—For patients with advanced-stage Hodgkin’s lymphoma, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) have superior efficacy to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), according to a study published online Dec. 10 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in...
Post
Scientists discover possible master switch for programming cancer immunotherapy
Study authors Adam Getzler, Dapeng Wang and Matthew Pipkin of The Scripps Research Institute collaborated with scientists at the University of California, San Diego. During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill...
Post
A new weapon against bone metastasis? Team develops antibody to fight cancer
These fluorescent images show bone metastases (green) that were treated with chemotherapy alone (left) or in combination with antibody 15D11 (right). When combined with the antibody developed by Princeton University’s Yibin Kang, …more In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects....